EN

Human Insulin R

Quick links

Choose a section

Quick links to important sections

Advertisements

Human Insulin R

Human Insulin R_EN
Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Human Insulin R

Property Description
Active Ingredient Insulin (Human)
Form Aqueous Solution for Injection
Pharmacological Class Antidiabetic Drug, Hypoglycemic Agent
Common Use Glucose Regulation / Metabolic Control
Origin Recombinant DNA Origin

What Type of Medicine is Human Insulin R?

Human Insulin R (also known as Soluble Insulin or Regular Insulin) is a biologic product classified as an antidiabetic drug and a hypoglycemic agent used for glucose regulation. It is an essential peptide hormone designated as a short-acting insulin preparation for patients requiring insulin therapy. This product is categorized within the pharmacological group of Insulin preparations.

Composition and Origin: Is Human Insulin R Synthetic?

The active ingredient in this medication is Insulin (Human), which is structurally identical to the hormone naturally produced by the pancreas. The product is not chemically synthetic; it is produced using recombinant DNA origin technology, a method recognized for producing high-purity Insulin preparations. Products created via recombinant DNA technology are designed to mirror the structure of natural human insulin. Human Insulin R is formulated as an aqueous solution for Injection and is a single active ingredient product, typically administered via the subcutaneous injection route.

General Purpose: Why is Soluble Insulin Used?

The primary purpose of this hypoglycemic agent is to achieve rapid and reliable metabolic control by managing elevated blood glucose levels. As a short-acting preparation, the medication is designed to quickly promote glucose uptake from the bloodstream into the body's cells, ensuring the sugar can be efficiently utilized. Its use is typical in situations where a quick, temporary drop in blood glucose is necessary. Essentially, it serves as a critical substitute for the body’s deficient or absent natural Insulin (Human), stabilizing the patient's blood sugar profile.

Regulatory References

  1. WHO Essential Medicines List (EML) for Insulin
  2. How Did They Make Insulin from Recombinant DNA?
  3. Human Insulin Injection Drug Information
Advertisements

What side effects are possible with Human Insulin R?

Possible Side Effects and Safety Information

The safety profile for Human Insulin R (Regular Insulin) is defined by officially documented adverse reactions and safety statements established by government regulatory authorities.

Frequency-Classified Adverse Reactions

The single most frequent adverse reaction is hypoglycemia (low blood sugar), which is classified as Very Common in regulatory documents. Other reactions are less frequent but documented:

  • Common: Local hypersensitivity reactions, such as redness, swelling, or itching at the injection site.
  • Uncommon: Lipodystrophy (changes in fat tissue at the injection site).
  • Very Rare: Severe systemic allergy, specifically anaphylactic reactions.

System and Serious Safety Concerns

The drug's safety profile includes effects grouped by system-organ classes, primarily affecting Metabolism and Nutrition (hypoglycemia, weight gain), the Immune System, and Skin and Subcutaneous Tissue.

Serious Adverse Reactions officially listed include:

  • Severe Hypoglycemia: May lead to loss of consciousness or temporary impairment of brain function.
  • Severe Hypokalemia: A decrease in potassium levels that can be life-threatening.
  • Fluid Retention: Risk of new or worsening heart failure when used with certain PPAR-gamma agonists.

Safety Considerations and Restrictions

Safety statements address conditions that affect risk or contraindicate use. Patients with renal or hepatic impairment may have altered insulin requirements, which increases the risk of hypoglycemia. Time-related patterns state that the risk of hypoglycemia is highest when the glucose-lowering effect is maximal.

Use is formally Contraindicated during episodes of pre-existing hypoglycemia or known hypersensitivity to the active substance or its excipients.

Advertisements

Overdose and Emergency Response

Overdose: When to Seek Help

Overdose of Human Insulin R results in a state known as hypoglycemia (very low blood sugar). This is the primary and most common adverse clinical consequence of taking too much insulin relative to food intake or energy expenditure.

Clinical Manifestations of Overdose

System Affected Potential Manifestations
Metabolic/Neurological Mild to severe hypoglycemia, which can progress to seizures, unconsciousness, and potentially permanent brain function impairment or death
Electrolyte Hypokalemia (low potassium levels), which can be life-threatening and may lead to respiratory paralysis or serious cardiac rhythm abnormalities

Required Emergency Actions

Urgent medical attention is required for any instance of severe hypoglycemia. Severe hypoglycemia is defined by the need for assistance from another person, the presence of unconsciousness, or the inability to consume sugar by mouth.

Regulatory information explicitly states that patients who are unable to eat or have lost consciousness require immediate parenteral glucose infusion or glucagon administration. Bystanders should immediately contact emergency services (e.g., 911) if the person is unconscious or cannot be roused. Additionally, close monitoring of potassium levels may be required, particularly in high-risk situations like intravenous insulin administration, due to the risk of life-threatening hypokalemia.

Advertisements

Therapeutic Uses of Human Insulin R

Comprehensive Management of High Blood Sugar

Human Insulin R is primarily used to address the symptomatic burden of conditions related to insufficient natural insulin, including Type 1, Type 2, and Gestational Diabetes. This medication is indicated to replace the insulin the body would normally make to control high blood sugar in people with diabetes. It is considered relevant for lowering elevated blood glucose levels (hyperglycemia) and supports the foundational goal of reducing the risk of chronic complications associated with high blood sugar.

It is also a relevant agent in acute care settings, commonly used in conditions marked by heightened symptoms like Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS), as well as to help manage symptoms related to systemic imbalance, such as hyperkalemia. This application provides supportive relief that assists with maintaining functional stability in critical scenarios.

“This short-acting insulin is a core tool in regimens designed to help patients manage the rapid glucose influx following meals.”

Quick Fact: Relief for Post-Meal Spikes As a short-acting agent, Human Insulin R is specifically applied in addressing the symptoms related to systemic imbalance that follow consuming a meal, known as postprandial hyperglycemia, thereby helping patients achieve a more stable and predictable blood sugar profile.

Regulatory References

  1. Human Insulin Injection: MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Official Eligibility Profile for Human Insulin R

The eligibility for Human Insulin R (Regular Insulin) is defined by official regulatory documentation, primarily based on the patient's medical condition and the absence of specific contraindications. The medicine is indicated for use in adults and pediatric patients diagnosed with Type 1 or Type 2 Diabetes Mellitus, establishing metabolic need as the core criterion for use.

Absolute Prohibitions (Contraindications)

Use of Human Insulin R is strictly contraindicated in two key circumstances:

  • Patients experiencing an episode of hypoglycemia (low blood sugar).
  • Patients with known hypersensitivity or allergy to Human Insulin or any of the product's inactive ingredients (excipients).

Conditional Use and Special Populations

While generally permitted, regulatory labels mandate caution and careful monitoring for certain groups:

  • Organ Impairment: Patients with renal impairment (kidney disease) or hepatic impairment (liver disease) are allowed to use the medicine, but a conditional approach is required due to potential changes in insulin requirements.
  • Pregnancy and Lactation: Treatment with Human Insulin R is not restricted during pregnancy or breastfeeding. Regulatory data have not established an association with adverse outcomes in these populations.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Human Insulin R primarily around pharmacodynamic effects that alter glucose control. These interactions are categorized based on their ability to either enhance or counteract the product’s glucose-lowering action, necessitating careful monitoring when co-administered.

Documented Pharmacodynamic Interactions

Interaction Type Examples of Interacting Medicinal Products
Increased Hypoglycemia Risk Oral Antidiabetic Agents, ACE Inhibitors, MAOIs, Salicylates, and Fibrates, which potentiate the insulin effect.
Decreased Hypoglycemia Risk Corticosteroids, Atypical Antipsychotics, Diuretics, Sympathomimetic Agents, and Thyroid Hormones, which counteract the insulin effect.

Other Official Interaction Constraints

Co-administration with medications that block the sympathetic nervous system, such as beta-blockers, is formally documented to mask the common warning signs of hypoglycemia. Regarding substances, Alcohol may either increase or decrease the blood glucose-lowering action of insulin, as noted in the official prescribing information. Furthermore, co-administration with Pioglitazone has been officially linked to the potential development or exacerbation of fluid retention and heart failure.

Regulatory labels for Human Insulin R do not document pharmacokinetic interactions related to CYP450 enzymes or specific transporter mechanisms.

Advertisements

Mechanism of Action

How Human Insulin R Works

Human Insulin R acts as an agonist for the Insulin Receptor (IR), a cell-surface transmembrane receptor expressed on virtually all cells, particularly concentrated in muscle, liver, and adipose tissue.

Binding to the IR initiates the intrinsic tyrosine kinase activity, activating the PI3K/Akt signaling pathway. In muscle and fat cells, this cascade rapidly promotes the translocation of GLUT4 glucose transporters to the cell membrane. This cellular action facilitates the immediate entry of glucose into the cells, resulting in a reduction of plasma glucose concentration.

In hepatocytes (liver cells), IR activation suppresses the activity of key enzymes involved in gluconeogenesis (glucose synthesis) and glycogenolysis (glycogen breakdown). This systematic suppression of endogenous glucose release contributes to a net decrease in basal plasma glucose concentration. Furthermore, the drug exerts an anabolic effect by inhibiting lipolysis and promoting protein synthesis across tissues, shifting metabolic processes toward energy substrate deposition.

Advertisements

Dosage and Administration Information

How to use Human Insulin R

The dosage of Human Insulin R (regular human insulin) must be individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goals.

Administration

Classification Detail
Route of Administration Subcutaneous injection (SC) or Intravenous infusion (IV). IV administration must occur only under medical supervision in a clinical setting.
Timing in Relation to Meals Subcutaneous injection should occur approximately 30 minutes before a meal.
Frequency Pattern Typically administered daily in a regimen with intermediate- or long-acting insulin. The U-500 concentration is generally administered two or three times daily.
Age Group Dosage is applicable to adults and children. Doses must be determined by a healthcare provider.
Missed Dose Patients should contact their doctor or pharmacist for specific instructions if a dose is missed.

Procedural Steps and Preparation

  1. Inspection: Visually inspect the solution before use. It must appear clear and colorless. Do not use if particulate matter or discoloration is observed.
  2. Injection Site: Inject into the thigh, upper arm, abdomen, or buttocks. Injection sites must be rotated within the same region from one injection to the next to reduce the risk of lipodystrophy.
  3. Mixing (SC): Do not mix Human Insulin R with insulin preparations other than Human Insulin N (NPH). When mixing, draw the Human Insulin R into the syringe first, and the mixture must be injected immediately.
  4. Syringe Use: When using the U-500 formulation from a vial, use only a U-500 insulin syringe to ensure correct dosage. Never share needles or syringes between patients.
Advertisements

Recent Clinical Evidence

Human Insulin R: Recent Clinical Evidence

Human Insulin R, or regular insulin, is a short-acting, non-modified form of insulin used to manage high blood sugar levels in individuals with diabetes mellitus. As a well-established medication, recent clinical research primarily focuses on optimizing its use within modern treatment regimens, combination therapies, and continuous subcutaneous insulin infusion (CSII) systems (insulin pumps).

Pharmacokinetic Profile and Timing

Recent studies have reinforced the drug's characteristic onset, peak, and duration of action. When administered subcutaneously, the onset of action is typically observed within 30 minutes, reaching a peak effect between 2 to 4 hours, and lasting for approximately 6 to 8 hours. This profile necessitates precise timing of injections relative to meals to prevent postprandial hyperglycemia and subsequent hypoglycemia.

Efficacy in Combination Regimens

Contemporary evidence supports the sustained efficacy of Human Insulin R as part of basal-bolus regimens. Its use is maintained when a flexible or immediate prandial correction is needed. Comparative studies often evaluate the effectiveness of rapid-acting insulin analogs against Human Insulin R, particularly concerning Time in Range (TIR), a key metric for glycemic control.

Efficacy Metric Human Insulin R Profile
Onset Slower than rapid analogs (approx. 30 min)
Peak Action Defined, broad peak (2–4 hours)
Hypoglycemia Risk Higher risk of late post-meal hypoglycemia

Safety and Tolerability

The primary safety concern across all insulin therapies, including Human Insulin R, remains hypoglycemia. Research continues to investigate strategies—such as continuous glucose monitoring (CGM) and optimized dosing—to mitigate this risk, particularly given the drug's prolonged peak action compared to newer analogs. Injection site reactions, lipodystrophy, and weight changes are also monitored across patient groups.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guideline NG18: Type 1 diabetes in adults: diagnosis and management

Advertisements

How should Human Insulin R be stored and disposed of?

Official Storage and Disposal Guidelines

Unopened Human Insulin R must be stored in a refrigerator (2 C to 8 C). It is critical not to freeze the insulin or expose it to excessive heat or direct light. The product should remain in its original carton for protection.

Once the vial or pen is in use, it must be stored at a controlled room temperature (typically leq 30 C or leq 25 C) and not refrigerated again. The in-use stability is limited to a specific period (commonly 28 days) after which the product must be discarded, even if medicine remains.

Disposal of Used Sharps: Needles and syringes must be placed immediately into a puncture-resistant container (sharps container) for safe disposal, in compliance with local regulations. Unused or expired medication should be disposed of via a drug take-back program or following local guidelines.

Advertisements

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Human Insulin R found in:

A-Z Index: